Mateusz Opyrchal is an Oncology physician affiliated with Indiana University Health. OpenAlex indexes 219 publications with 2,844 citations (h-index 28); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1701 N Senate Blvd
Indianapolis, IN 462021239
Telephone
888-484-3258Provider last certified this registry record 15 Mar 2025.
Clinical trials
- Organoid Model Predictive of Response to Immunotherapies
Sponsor: Indiana University
- Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast Cancer
Sponsor: Washington University School of Medicine
- Study of Oral PQR309 in Patients With Advanced Solid Tumors
Sponsor: PIQUR Therapeutics AG
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
21 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Regeneron Pharmaceuticals, Inc.Program year20257 payments
- Gilead Sciences, Inc.Program year20253 payments
- Novartis Pharmaceuticals CorporationProgram year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
92.2%Aromatase Inhibitor78.7%Letrozole73%Anastrozole27%Part D≥76 patientsEstrogen Agonist/Antagonist10.5%Tamoxifen Citrate100%Part D≥16 patients+ 1 more class in this area
Sensory organs
5%Corticosteroid5%Dexamethasone100%Part D<11 patientsNervous system
2.8%SSRI2.8%Trazodone Hcl100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2023–2026 per NIH RePORTER. The latest:
- Targeting FOXP3 mRNA splicing for breast cancer immunotherapy
Indiana University Indianapolis
FY2026$585,212R01CA282917 - Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy
Indiana University Indianapolis
FY2026$501,827R01CA260274 - Targeting FOXP3 mRNA splicing for breast cancer immunotherapy
Indiana University Indianapolis
FY2025$585,212R01CA282917
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Douglas Zipes, MD
Indiana University Health
Lawrence Einhorn, MD
Indiana University Health
Lisa Landrum, MD
Indiana University Health
Patrick Loehrer, MD
Indiana University Health
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”